Health Canada approves Rinvoq for adults with moderately to severely active ulcerative colitis
AbbVie announced that Health Canada approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]), an oral, once-daily selective and reversible JAK inhibitor, for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of response to, or intolerance to at least one of conventional, and/or biologic therapy
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease (IBD) of the large intestine that can lead to substantial burden and often disability among patients. Canada has one of the highest rates of inflammatory bowel disease in the world, the two main forms of which are Crohn's disease and ulcerative colitis. More than 300,000 Canadians are living with IBD, and the rate of diagnosis is increasing amongst certain demographics including seniors.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.